Introduction
Heart failure (HF), a leading cause of morbidity and mortality in the developed world, continues to increase in incidence. 1, 2 The mortality rates of HF remain largely unchanged despite several advances in the management of cardiovascular disease. 3, 4 Hospitalizations for acute heart failure (AHF) account for a significant portion of the human and economic burden of HF. 3 Attention focused in recent years on determining predictors of HF mortality and readmissions in order to trigger targeted interventions for high-risk patients. Several predictors have been identified, most of which are non-modifiable demographic, physiological, or functional factors. Interventions that are likely to improve outcomes such as guideline medical therapy, disease management programs, and early post-discharge follow-up are already part of the current standard of care. Identification of new modifiable risk factors may provide an opportunity to decrease mortality. 5 -10 Sleep disordered breathing (SDB) is the most common comorbidity in patients with HF. 11 Sleep disordered breathing is associated with neurohumoural and clinical perturbations that can decompensate stable HF. 12, 13 The negative impact of SDB might be most pronounced during AHF hospitalizations and in the immediate post-discharge period. We recently found that newly diagnosed SDB during hospitalization for AHF is a novel independent predictor of HF readmissions. 14 From this background, we hypothesized that SDB would be an independent predictor of post-discharge mortality as well.
Methods

Study population and participants
All patients who were hospitalized at the Ohio State University (OSU) Ross Heart Hospital with an admission diagnosis of heart failure between January 2007 and December 2010 were targeted for enrolment. Only HF patients with reduced left ventricular ejection fraction (LVEF ≤ 45%) (HFrEF) were included in this study. Acute heart failure was defined according to the standard clinical guidelines as having a chief complaint of dyspnoea or fatigue, and at least one sign and one symptom of elevated left ventricular pressure. Sleep study orders are part of the electronic admission order set for heart failure at the OSU Ross Heart Hospital and are performed regardless of any screening or risk factors for SDB. Patients who were already diagnosed with SDB or were on treatment did not receive the in-hospital sleep study. Figure 1 details the disposition of AHF patients in the study and describes the screening and testing process.
Sleep studies and group definitions
The in-hospital sleep studies were attended cardiorespiratory studies (Stardust II, Respironics, Inc.) that measure respiratory effort, oxygen saturation, nasal flow, and pulse rate. Cardiorespiratory polygraphy is widely used for the diagnosis of obstructive sleep apnoea (OSA) and central sleep apnoea (CSA) in patients with HF. 11, 15, 16 We have reported on our validation of in-hospital testing in AHF patients and its high positive predictive value (.90%) for the persistence of OSA 17 and CSA 14 against polysomnography done in the stable outpatient state. Trained night shift nurses who noted the patients' visual sleep and wakefulness and any interruptions to sleep attended the in-hospital sleep studies. The nurse also ensured the integrity of the recording by checking and reapplying leads as needed. Patients were considered for the sleep study starting on the second night of hospitalization. The sleep studies were not done on patients who are unstable, moderately hypoxic (oxygen saturation ,87% on room air), haemodynamically unstable, or unable to sleep in ,308 position. Attempts were made on subsequent nights during the hospitalization to perform the sleep studies when these patients became more stable. Studies were interrupted or terminated if the patient became unstable. Segments of the study that included simultaneously more than one missing signal were subtracted from the recording time. An intact effort signal was required for any segment to be interpretable. Respiratory event scoring and classification of OSA and CSA were according to standard clinical criteria 18 and used oxygen desaturation cut-off of 3% for hypopneas (no arousal criterion is used). An AHI cut-off of 15 events/hour was selected for the in-hospital study to mitigate against the expected increase in respiratory control instability and oxygen desaturation during the AHF episode. 
Follow-up procedure and classification of patients by treatment status
In-hospital sleep testing was instituted by the OSU Sleep Heart Program as a clinical screening program in 2005. Patients and physicians were aware that the purpose of the in-hospital sleep studies was screening andthat follow-up was to be arranged in the outpatient setting if the studies were positive for SDB. All patients who tested positive for SDB were informed of their diagnosis prior to discharge and were provided follow-up appointments at the OSU Sleep Center prior to their discharge. Patients were also sent reminder letters in the first year post-discharge. Some patients elected to follow-up locally and others did not follow-up. In order to explore the relation between treatment status and changes in the risk of post-discharge mortality, we classified patients as treated and untreated in the first year post discharge. Patients who were confirmed by download or Sleep physician report to have been using the treatment device .4 h/night between 6 and 12 months post-discharge were classified as 'treated'. Patients who were classified as 'untreated' were patients who rejected device therapy; were still in the process of obtaining and starting device therapy in the 6-12 months post-discharge; or may have been on device therapy but the adherence was not verifiable by review of the records.
Statistical design and analysis
We described the baseline characteristics of the study population using frequencies with percentages for categorical variables and means with standard deviation (SD) for continuous variables. We planned a primary hypothesis test that compared post-discharge all-cause mortality of screen identified CSA patients with patients who screened negative (nmSDB). We also planned to compare screen identified OSA patients with the screen negatives. All analyses were performed using SAS 9.2 (SAS Inc., Cary NC, USA, 2009).
The comparisons were made within a Cox proportional hazards model with time to death as the outcome. The model adjusted for a set of covariates that were found previously to distinguish severity or to predict negative outcomes in HF patients. 7, 19 The covariates used in the model are listed in Table 1 . Note that we used all variables with no R. Khayat et al.
selection process to ensure that the reported SDB effects could not be explained by any of these measures of risk or severity. To adjust for testing two hypotheses (CSA and OSA vs. nmSDB), we used Holms procedure, 20 and so strongly controlled the overall type 1 error rate for the two tests at a ¼ 0.05. Double-sided testing was used to generate P-values. The sample size was determined to have at least 80% power to detect a 60 -70% increase in mortality for the CSA and OSA hypothesis tests. Sixty-three per cent of the patients were included in a previously published analysis of effect of CSA on 6 months readmissions only; but mortality analysis was not done prior to this analysis; and mortality data
were not yet collected. 14 In a sensitivity analysis, we applied the same Cox proportional hazards model using time to last follow-up (outpatient visit or readmission date) as the censoring time, rather than the study close out date. To explore whether treatment for SDB modifies the mortality rate, only patients with at least 6 months survival post-discharge were included. This ensured that patients in this exploratory analysis had the opportunity to receive treatment. We fit a Cox proportional hazards model for mortality, which included SDB group, treatment status, and the interaction between SDB group and treatment status, along with all of the covariates from the primary model. Parameter contrasts were constructed to obtain the hazard ratios (HRs) vs. the nmSDB group.
Results
Patient characteristics
During the study period, interpretable studies were done on 1117 consecutive hospitalized patients with AHF and LVEF ≤ 45%. Of these patients, 344 had CSA, 525 had OSA, and 248 had nmSDB. In-hospital death occurred in 21 patients: 6 CSA (2%), 12 OSA (2%), and 3 (1%) patients with nmSDB. These patients were excluded from the post-discharge mortality analysis reported below.
Patients' characteristics were similar to other large registries and clinical trials of hospitalized HF patients. 9 Group characteristics are listed in Table 1 . Most patients had decompensation of previously recognized HFrEF, and a minority (n ¼ 36) had de novo AHF. The most common causes of decompensation were arrhythmia, ischaemic events, and pneumonia. There were expected differences among the groups in baseline characteristics including cardiac function, weight, and age that were consistent with previous reports of patients with HF and SDB. 11, 17 As noted previously, all characteristics listed in Table 1 were included as covariates in the proportional hazards model reported below. The median follow-up time was Sleep disordered breathing and post-discharge mortality in heart failure 35.8 months (IQR 22.3-36.0 months). Table 2 includes the parameters of the in-hospital sleep study on all patients.
Effect of sleep disordered breathing on post-discharge morality
Effect of central sleep apnoea on post-discharge mortality Newly diagnosed CSA proved to be a risk factor for post-discharge mortality. Figure 2 is the Kaplan -Meier survival curve comparing SDB groups to nmSDB. The univariable HR for time to death over 36 months was 2.17 (95% CI, 1.5, 3.1), P , 0.001. For the primary hypothesis test, the multivariable HR was 1.61 (95% CI: 1.1, 2.4) P ¼ 0.02 (meeting the Holms first significance cut-off of 0.025) Table 3 details the Cox proportional hazards models for time to death over the 3-year follow-up for the three groups. Using the sensitivity analysis with the date of last encounter instead of time to death increased the multivariable HR slightly (HR ¼ 1.77).
The effect of CSA on mortality at 1, 2, and 3 years is reported in Table 4 .
Effect of obstructive sleep apnoea on post-discharge mortality Similar to CSA, OSA was an independent risk factor for postdischarge mortality. The multivariable HR for OSA vs. nmSDB was 1.53 (CI, 1.1, 2.2), P ¼ 0.02, also significant ( mortality was substantial in all of the 3 years of follow-up as noted in Table 4 and Figure 2 .
Over the 3-year follow-up, the unadjusted mortality rates were: CSA 110 (34%), OSA: 153 (32%), and nm-SDB 40 (17%). Because the HRs were similar for CSA and OSA, we obtained a combined group HR, the SDB univariable HR for time to death over 36 months was 2.09 (1.5, 2.9) P , 0.001, and the multivariable ratio was 1.57 (1.1, 2.2) P ¼ 0.01.
Exploration of a modification of the mortality effect with sleep disordered breathing treatment
In the first year post-discharge, 58 CSA patients and 103 OSA patients were verified to have been on positive airway pressure therapy with adequate adherence as defined above. Two hundred and six patients with CSA and 337 patients with OSA were not confirmed to be on therapy by the end of the first year post-discharge and were classified as untreated. Table 5 lists the comparisons in HRs between the groups by treatment status and the reference nmSDB group. Figure 3 is a survival plot of patients by treatment status. Note that the SDB mortality effect for those in the untreated group is more pronounced than those reported above for the overall SDB groups and is absent in the subjects who elected treatment. This could be due to confounding as discussed below.
Other predictors of post-discharge mortality
The covariates used in the proportional hazards modelling for the SDB effect are listed in Table 6 . These covariates are similar to previously reported predictors of mortality post-discharge in large registries of HF admissions. 7, 19, 21 We explored the SDB and gender interaction and the BMI and SDB interaction effects on mortality and both were not significant. We also explored whether using a continuous measurement for systolic blood pressure (instead of the dichotomy) changed the results, and it did not.
Discussion
This prospective, single-centre cohort study is the first evaluation of the effect of SDB on post-discharge mortality in patients with AHF and reduced LVEF. Furthermore, this report is the largest prospective evaluation of the effect of SDB on mortality in HF patients. Newly diagnosed CSA or OSA on a surveillance in-hospital sleep-testing program are both independently associated with post-discharge mortality in patients with systolic HF who are hospitalized for AHF. Based on the multivariable models, these increased risks cannot be explained by severity, demographics and any other baseline patient's characteristics listed in Table 1 . Interestingly, exploratory analysis based on treatment status suggests the association between SDB and mortality is not persistent in the treated group. Compared with the other predictors of post-discharge mortality and poor outcome in HF, SDB is potentially treatable and may provide an opportunity to impact the outcome of HF hospitalizations. Important studies have reported on independent relationship between SDB and mortality in untreated patients with chronic stable HF. 22 -24 This study was designed as a prospective cohort in all hospitalized patients with AHF avoiding the potentially biasing effect of referral to the sleep facility. The primary analysis of this study included all patients regardless of their treatment status and only explored the difference in the mortality experience between patients who accepted and pursed treatment and the remainder of the patients. The cause of death in the majority of patients was congestive HF, which can be related to dysrhythmic, or neurohumoural complications of SDB as recently shown. 12 The population of this study is similar in characteristics and event rate to populations of large registries and trials in hospitalized HF patients, making the findings immediately generalizable to clinical practice. 21 The device (Stardust II) used in this study for the in-hospital identification and classifications of SDB is a limitation. The device uses one effort belt resulting in a relatively large number of recording failures ( Figure 1) . We mitigated this problem by direct observation by nurses who replaced any displaced belts or sensors. In addition, the nurses documented visual sleep resulting in improved detection of events. We also were able to repeat studies on subsequent nights of hospitalization in patients with recording failure. Another consideration in testing during the decompensation episode is that the occurrence or severity of SDB may be increased by increased cardiac filling pressure. 25 We have validated this technique, approach, and interpretation against outpatient polysmnography previously. Despite some decrease in AHI on the outpatient polysmnography, the positive predictive value for SDB was excellent.
14,17
The use of cardiorespiratory polygraphy instead of polysomnography for the detection and classification of SDB during the hospitalization is critical for providing a practical and generalizable method of case finding in this high-risk population and setting.
The effect of treatment of either CSA or OSA on survival in HF patients remains unknown. Exploratory analysis in this study suggests that treated patients had survival similar to patients with nmSDB. Although it appears as if treatment eliminates the increased mortality due to SDB, confounding effects associated with the type of patients who seek SDB treatment could explain this result. Note also that those classified as untreated could have received SDB treatment after the first year, which means the untreated HRs could be conservatively biased. This observation supports the need for adequately powered trials evaluating treatment effects on post-discharge outcomes. Pilot studies with adaptive servo ventilators demonstrate a beneficial effect on outcomes of chronic HF. 26 SDB remains largely undiagnosed in the majority of patients with HF. 28 The independent mortality effect of SDB along with the previously demonstrated effect on readmissions 14 , initial length of stay 22 days, creatinine 1.6 mg/dL, admission Na 4.1 mg/dL, admission haemoglobin 4.7 g/dL, BUN 16.7); the remaining covariates were dichotomized or trichotomized (race, cardiomyopathy).
